Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 3
1963 2
1966 1
1968 1
1969 1
1971 1
1972 1
1973 1
1977 1
1978 2
1980 1
1983 1
1985 1
1986 3
1987 1
1988 2
1989 1
1990 5
1991 2
1992 12
1993 5
1994 11
1995 11
1996 6
1997 17
1998 21
1999 18
2000 31
2001 40
2002 49
2003 53
2004 50
2005 61
2006 64
2007 80
2008 76
2009 105
2010 127
2011 134
2012 119
2013 104
2014 131
2015 106
2016 93
2017 90
2018 87
2019 105
2020 99
2021 117
2022 89
2023 69
2024 71
2025 55

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,067 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: chung ij. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. Kang YK, et al. Among authors: chung ij. J Clin Oncol. 2021 Sep 10;39(26):2903-2913. doi: 10.1200/JCO.20.02914. Epub 2021 Jun 16. J Clin Oncol. 2021. PMID: 34133211 Free PMC article. Clinical Trial.
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Cheong JH, Jeong O, Heo MH, Kim HK, Park C, Yoo CH, Kang SY, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Hwang JE, Ryu SW, Kook MC, Ryoo BY, Kim H, Yoo MW, Lee NS, Lee SH, Noh SH. Kang YK, et al. Among authors: chung ij. J Clin Oncol. 2024 Sep 1;42(25):2961-2965. doi: 10.1200/JCO.23.02167. Epub 2024 Jul 12. J Clin Oncol. 2024. PMID: 38996201 Clinical Trial.
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, Kadowaki S, Tsuji K, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Sym SJ, Chen LT, Chen JS, Bai LY, Nakada T, Hagihara S, Makino R, Nishiyama E, Kang YK. Boku N, et al. Among authors: chung ij. Gastric Cancer. 2024 Nov;27(6):1287-1301. doi: 10.1007/s10120-024-01535-0. Epub 2024 Aug 20. Gastric Cancer. 2024. PMID: 39162872 Free PMC article. Clinical Trial.
Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Chudasama P, et al. Among authors: chung i. Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0. Nat Commun. 2018. PMID: 29321523 Free PMC article.
Pediatric Narcolepsy-A Practical Review.
Chung IH, Chin WC, Huang YS, Wang CH. Chung IH, et al. Children (Basel). 2022 Jun 29;9(7):974. doi: 10.3390/children9070974. Children (Basel). 2022. PMID: 35883958 Free PMC article. Review.
Bilateral lumbar hernia.
Chung I, Wong KY. Chung I, et al. Hong Kong Med J. 2019 Feb;25(1):78-80. doi: 10.12809/hkmj187410. Hong Kong Med J. 2019. PMID: 30713147 Free article. No abstract available.
Arrhythmias in Chronic Kidney Disease.
Akhtar Z, Leung LW, Kontogiannis C, Chung I, Bin Waleed K, Gallagher MM. Akhtar Z, et al. Among authors: chung i. Eur Cardiol. 2022 Mar 7;17:e05. doi: 10.15420/ecr.2021.52. eCollection 2022 Feb. Eur Cardiol. 2022. PMID: 35321526 Free PMC article. Review.
Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-β1 (TGF-β1) availability and inhibits hepatocarcinogenesis.
Kim DH, Sung M, Park MS, Sun EG, Yoon S, Yoo KH, Radhakrishnan K, Jung SY, Bae WK, Cho SH, Chung IJ. Kim DH, et al. Among authors: chung ij. Cancer Commun (Lond). 2024 Oct;44(10):1106-1129. doi: 10.1002/cac2.12600. Epub 2024 Jul 28. Cancer Commun (Lond). 2024. PMID: 39073023 Free PMC article.
2,067 results